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Abbreviations 
ANZDATA – Australia and New Zealand Dialysis and Transplant 
ANOVA - analysis of variance  
CAN/IFTA – chronic allograft nephropathy/interstitial fibrosis and tubular atrophy 
CI – confidence interval 
DCD - donation after circulatory death 
DCGL – death-censored graft loss 
DGF – delayed graft function 
ESKD – end-stage kidney disease 
HLA – human leukocyte antigen 
HR – hazard ratio 
IQR – interquartile range 
KDPI - Kidney donor profile index  
PRA – panel reactive antibody 
SD – standard deviation 
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Abstract 
Background: Prolonged duration of delayed graft function (DGF) may be associated with 
adverse allograft outcomes, but the association between threshold duration of DGF, acute 
rejection and long-term allograft loss remains undefined. We aimed to determine the impact of 
DGF duration on allograft outcomes and to assess whether this association was mediated by 
acute rejection. Methods: Using data from the Australian and New Zealand Dialysis and 
Transplant (ANZDATA) registry, Cox proportional modelling was used to determine the 
association between quartiles of DGF duration, acute rejection at 6 months and death-censored 
graft loss (DCGL). Mediation analysis was conducted to determine whether acute rejection was a 
causal intermediate between DGF and DCGL. Results: Of 7668 deceased donor kidney 
transplants between 1997-2014, 1497 (19.5%) recipients experienced DGF requiring dialysis. 
The median (interquartile range) duration of DGF was 7(9) days, with 25% requiring dialysis for 
≥14 days. Among recipients who had experienced DGF duration of 1-4 days, the adjusted HR for 
duration of 5-7, 8-13 and ≥14 days were 1.13 (95%CI 0.83-1.55;p=0.43), 1.44 (1.08-
1.91;p=0.013), and 1.99 (1.50-2.65;p<0.001), respectively for acute rejection; and were 1.10 
(0.73-1.67;p=0.64), 1.45 (1.00-2.11;p=0.05) and 1.60 (1.10-2.31;p=0.01), respectively for 
DCGL. On average, 8% of the effects between DGF duration and DCGL were explained by 
acute rejection.  Conclusions: There was a direct dose-dependent effect between DGF duration 
and DCGL, with acute rejection explaining <10% of the effects between DGF duration and 
DCGL. Future research identifying other potential modifiable mediators that lies in the causal 
pathway between DGF duration and allograft loss is essential. 
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Introduction 
The incidence of delayed graft function (DGF) following kidney transplantation has increased 
substantially over time, following the increased utilization of kidneys from marginal donors 
(higher kidney donor profile index [KDPI]) and donation after circulatory death (DCD) 
1
. 
Between 2000 and 2009, the incidences of DGF exceeded over 20% for brain death donors and 
50% for DCD transplants in Australia
2
. Similar rates of DGF have been reported in the United 
States and United Kingdom 
3,4
. 
 
DGF may have an unfavourable impact on allograft outcomes, such as premature allograft loss, 
attributed to excess inflammatory response, increased hypoxic injury and damage to endothelial 
and tubular cells triggered by ischemic-reperfusion injury
5-8
. In a meta-analysis of 33 studies 
totalling 151,594 kidney transplant recipients, DGF was associated with over a 40% greater risk 
of allograft loss 
4
. While an association between DGF and early graft loss was found, 
uncertainties exist as to the threshold duration of DGF associated with adverse allograft 
outcomes
9,10
. In addition, prior studies have reported higher incidence rates of acute rejection 
during DGF. The reasons for the observed increased risk may be multifactorial, with indirect 
activation of the innate and adaptive immunity through ischaemic-reperfusion injury likely a key 
driver for acute rejection and subsequent graft dysfunction
11-14,15
. This study aimed to examine 
the associations between DGF status, DGF duration and allograft outcomes; and to determine if 
the relationship between DGF duration and allograft loss was mediated by acute rejection in 
deceased donor kidney transplant recipients. 
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Methods 
Study population 
Patients with end-stage kidney disease (ESKD) who received a first deceased donor kidney 
transplant and experienced DGF between 1997 and 2014 in Australia and New Zealand were 
included. Patients who had received live donor kidney transplants, multiple organ grafts and 
those who had received prior grafts were excluded. In Australia and New Zealand, deceased 
donor kidneys are typically allocated to ABO-compatible transplant candidates with negative 
complement-dependent cytotoxicity (CDC) T cell cross-match. 
 
Exposure factor 
DGF was defined as requiring any dialysis within 72 hours posttransplant. The duration of DGF 
was defined as the number of days that dialysis was required, with Australia and New Zealand 
Dialysis and Transplant (ANZDATA) registry collecting the dates of the last posttransplant 
dialysis in recipients who had experienced DGF. Kidney transplant recipients with a DGF 
duration that was either not recorded (n=305) or recorded as being 0 days (n=11) or >35 days 
(n=77) were excluded from this study (total n=393). Even though the commonly accepted 
definition for DGF is dialysis within 7 days posttransplantation 
16
, the definition used by the 
ANZDATA registry for DGF is dialysis within 72 hours posttransplantation, which captured all 
recorded cases of DGF (even if DGF was defined as dialysis within 7 days). Of the 5778 
recipients who did not experienced DGF, only 3 (0.05%) had dialysis after 2 weeks after 
transplantation (which were unlikely to represent DGF) and therefore were not included in the 
DGF cohort. 
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Data collection 
The following data were extracted from the registry: donor age, gender and DCD status; 
recipient age, gender, duration of waiting time, ethnicity, ESKD cause, body mass index and 
comorbidities at time of transplant (diabetes, coronary artery disease and peripheral vascular 
disease); immunological factors of sensitization status (ie, percentage panel reactive antibodies 
[%PRA]) and human leukocyte antigen (HLA)-mismatches; transplant era, initial 
immunosuppression at time of transplant (calcineurin-inhibitor [none, cyclosporin or tacrolimus], 
antimetabolite –none, azathioprine or mycophenolic acid] and prednisolone) and use of induction 
therapy (interleukin-2-receptor, T cell depleting antibodies or rituximab).  
 
Clinical Outcomes 
The outcomes of this study included acute rejection at 6 months (recorded as biopsy-proven), 
death-censored graft loss (DCGL), and overall graft loss.  
 
Statistical analyses  
Data were expressed as number (proportion), mean (standard deviation [SD]), and median 
(interquartile range [IQR]), where appropriate. Associations between DGF duration and baseline 
characteristics were analyzed using chi-square test, analysis of variance (ANOVA) or Kruskal 
Wallis test. Restricted cubic spline was used to determine the linearity of the association between 
DGF duration and allograft outcomes. The associations between DGF status and outcomes, and 
between DGF duration and outcomes were examined using the adjusted Cox proportional hazard 
regression analysis. Covariates with p values of <0.10 in the unadjusted analyses or covariates 
with established biological relationships with outcomes (eg, ethnicity, donor and recipient age) 
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were included in the multivariable-adjusted analyses. The proportional hazard assumptions of all 
models were checked graphically by plotting the Schoenfeld residuals. Results were expressed as 
hazard ratio (HR) with 95% confidence interval (95%CI). A sensitivity analysis was undertaken 
to determine the association between DGF duration and graft loss after excluding allografts that 
have failed within the first month posttransplant. 
 
Mediation analysis allowing for exposure-mediator interactions was used to test whether acute 
rejection was a mediator between the exposure (DGF duration) and allograft outcomes (DCGL 
and overall graft loss), with the proportion and total effects that were mediated by both the direct 
(ie, the part of the exposure [DGF duration] that was not mediated by acute rejection) and 
indirect effects (ie, the part of the exposure [DGF duration] that was mediated by acute rejection) 
determined (Figure S1). A mediator is the variable that often lies in the causal pathway and 
account for the direction and magnitude of the effect between the exposure factor (ie, duration of 
DGF) and the outcomes of interest (DCGL and overall graft loss) 
17,18
. Figure S1 shows 
diagrammatically the differences between covariates, moderator and mediator. The associations 
between DGF duration and acute rejection at 6 months and between acute rejection at 6 months 
and DCGL or overall graft loss were examined using adjusted Cox regression analyses.  
 
Statistical evaluations were performed by STATA version 11 and SAS 9.4. P values of <0.05 
were considered statistically significant. The SAS macro used for the mediation analysis is 
shown as an online appendix by Valeri L and VanderWeele TJ 
19
.  
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Results 
Study population 
There were 7668 deceased donor transplants performed during the study period, of which 5778 
(75.4%) recipients did not experienced DGF and 1890 (24.6%) had experienced DGF (393 
[20.8%] were excluded leaving 1497 [79.2%] recipients available for analysis). Of the 393 
recipients excluded from the study, there were a higher proportion of recipients who had 
experienced DCGL compared to the study cohort (49.4% vs. 16.8%, p<0.001). However, the 
proportion of patients experiencing acute rejection at 6 months was similar (31.8% vs. 33.3%, 
p=0.264). Recipients in the excluded cohort were more likely to have received older donor 
kidneys (mean [SD] donor age 49.6 [15.3] vs. 47.6 [16.3] years, p=0.024), but recipient age 
(mean [SD] 46.8 [13.1] vs. 45.4 [13.5] years, p=0.059), total ischaemic time (mean [SD] 13.7 
[4.9] vs. 14.0 [4.9] hours, p=0.285), HLA-mismatches (mean [SD] 3.6 [1.6] vs. 3.6 [1.7] 
mismatches, p=0.638) and proportion of DCD kidneys (20.6% vs. 23.9%, p=0.167) were similar 
to the study cohort.  
 
Of the 1497 primary deceased donor kidney transplant recipients who had experienced DGF 
during the study period, the median (interquartile range [IQR]) duration of DGF was 7 (9) days, 
with 25% of recipients who had experienced DGF had required dialysis for at least 14 days 
posttransplant.  The median (IQR) graft and patient follow-up periods were 4.2 (6.3) and 4.9 
(7.3) years, resulting in 8564 and 9587 graft- and patient-years, respectively. The relationship 
between DGF duration, DCGL and overall graft loss were linear (Figure S2 for DCGL). DGF 
duration was categorized into quartiles (1-4 days, 5-7 days, 8-13 days and ≥14 days) and 
incremental 5-days interval for analysis.  
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The characteristics of the entire cohort stratified by DGF status are shown in Table S1. 
Recipients who did not experience DGF were younger, less likely to have received DCD 
kidneys, less likely to have received induction therapy, and were more likely to have received 
younger donor kidneys, compared to recipients who had experienced DGF. The majority of the 
recipients with or without DGF had received calcineurin-inhibitor (96% vs. 98%; with over 50% 
of recipients initiated on tacrolimus), mycophenolic acid (91% vs. 89%) and prednisolone (97% 
vs. 97%).  
 
Table 1 shows the baseline characteristics stratified by DGF duration in quartiles. Recipients 
with prolonged DGF were more likely to have received DCD kidney transplants, be highly 
sensitized, have waited longer on dialysis, have not received induction therapy and have received 
donor kidneys with a longer mean total ischaemic time. The proportion of recipients with 
prolonged DGF had reduced over successive eras (1997-2002: 58%, 2003-2008: 52%, 2009-
2014: 43% required over 7 days of dialysis; p<0.001). The characteristics of the excluded 
(n=393) cohort with DGF were similar, with mean (SD) recipient age (50.9 [12.9] vs. 49.6 
[13.5], p=0.075), mean (SD) number of HLA-mismatches (3.6 [1.6] vs. 3.6 [1.7], p=0.638) and 
proportion of recipients who had received DCD kidneys (21% vs. 24%, p=0.167) not 
significantly different to the included cohort. The proportions of recipients who had experienced 
acute rejection in the excluded and included cohorts were similar [31% and 29%, p=0.231].  
 
Causes of DCGL 
Chronic allograft nephropathy/interstitial fibrosis and tubular atrophy (CAN/IFTA) was the 
predominant cause of DCGL across quartiles of DGF duration (1-4 days: 66%, 5-7 days: 66%, 8-
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13 days: 61%, ≥14 days: 60%), followed by acute rejection (1-4 days: 4%, 5-7 days: 15%, 8-13 
days: 11%, ≥14 days: 15%) and recurrent or de novo glomerulonephritis (1-4 days: 4%, 5-7 
days: 2%, 8-13 days: 11%, ≥14 days: 8%, p value for trend = 0.230) (Figure 2). 
 
Association between DGF, DCGL and overall graft loss 
Compared to recipients who did not experience DGF, recipients with DGF were more likely to 
develop DCGL (adjusted HR 1.34, 95%CI 1.15, 1.56; p<0.001) and overall graft loss (adjusted 
HR 1.28, 95%CI 1.15, 1.43; p<0.001). The Kaplan Meier failure curves for DCGL and overall 
graft loss are shown in Figures 1A and 1B, respectively. 
 
Association between DGF duration and DCGL 
Compared to DGF duration of 1-4 days, the adjusted HR (95%CI) for DCGL for each category 
of DGF duration in ascending order were 1.10 (0.73, 1.67; p=0.638), 1.45 (1.00, 2.11; p=0.05) 
and 1.60 (1.10, 2.31; p=0.01), respectively (Table 2 and Figure 3). For every 5-day increase in 
DGF duration, the adjusted HR (95%CI) for DCGL was 1.11 (1.02, 1.20; p=0.011). Other 
covariates associated with DCGL are shown in Table 2. The Kaplan Meier failure curves for 
DCGL stratified by quartiles of DGF duration are shown in Figure 4A.  
 
Association between DGF duration and overall graft loss 
Compared to DGF duration of 1-4 days, the adjusted HR (95%CI) for overall graft loss for each 
category of DGF duration in ascending order were 1.25 (0.95, 1.65; p=0.113), 1.24 (0.95, 1.62; 
p=0.12) and 1.44 (1.11, 1.88; p=0.006), respectively (Table 2 and Figure 3). For every 5-day 
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increase in DGF duration, the adjusted HR (95%CI) for overall graft loss was 1.08 (1.01 -1.14; 
p=0.014). Other covariates associated with overall graft loss are shown in Table 2.  
 
Association between DGF duration and acute rejection at 6 months 
The majority of the acute rejections (70%) occurred within the first month posttransplant. Of 
those who had experienced acute rejection within 6 months posttransplants, 9%, 26%, 54% and 
74% of acute rejection episodes occurred during DGF durations of 1-4 days, 5-7 days, 8-13 days 
and ≥14 days, respectively. Compared to a DGF duration of 1-4 days, the adjusted HR (95%CI) 
for categories of DGF duration in ascending order were 1.13 (0.83, 1.55; p=0.428), 1.44 (1.08, 
1.91; p=0.013), and 1.99 (1.50, 2.65; p<0.001), respectively, independent of HLA-mismatches, 
%PRA, ethnicity, donor and recipient age. For every 5-day increase in DGF duration, the 
adjusted HR (95% CI) for acute rejection was 1.17 (1.10, 1.25; p<0.001).  The Kaplan Meier 
failure curves stratified by quartiles of DGF duration for acute rejection at 6 months are shown in 
Figure S3.  
 
Association between acute rejection at 6 months, DCGL and overall graft loss 
Compared to recipients who did not develop acute rejection at 6 months, those who developed 
acute rejection at 6 months were more likely to experience DCGL and overall graft loss with 
adjusted HR (95%CI) of 1.56 (1.02, 2.04; p=0.001) and 1.36 (1.12, 1.65; p=0.002), respectively, 
independent of HLA-mismatches, %PRA, ethnicity, donor and recipient age.  
 
Mediation effects of acute rejection between DGF duration, DCGL and overall graft loss 
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Table 3 shows the estimates of the direct, indirect and total effects between DGF duration and 
DCGL and overall graft loss. The proportion of the effect between DGF duration and DCGL 
mediated by acute rejection was 0.084 (ie, 8.4% of the effect between DGF duration and DCGL 
is explained by acute rejection). Similarly, the proportion of the effect between DGF duration 
and overall graft loss mediated by acute rejection was 0.087 (ie, 8.7% of the effect between DGF 
duration and overall graft loss was explained by acute rejection).  
 
Sensitivity analysis 
There were 17 allografts (1.1% of study cohort) that had failed within the first month 
posttransplant with 5 cases attributed to vascular complications, 2 cases due to acute rejection, 2 
cases due to haemolytic uraemic syndrome and 8 cases due to other/unknown causes (3 of 17 
[18%] allograft failure within 3 days of transplant). Following exclusion of these allografts, the 
associations between quartiles of DGF duration or every 5-day incremental increase in DGF 
duration and outcomes remained unchanged. Compared to recipients who had experienced DGF 
duration of 1-4 days, those who had experienced DGF duration of at least 14 days were more 
likely to develop DCGL and overall graft loss, with adjusted HR (95%CI) of 1.65 (1.13, 2.41; 
p=0.003) and 1.48 (1.14, 1.93; p=0.012), respectively. For every 5-day increase in DGF duration, 
the adjusted HR (95%CI) for DCGL and overall graft loss were 1.12 (1.03, 1.21; p=0.006) and 
1.09 (95%CI 1.03, 1.15; p=0.005), respectively. The Kaplan Meier failure curves for DCGL 
stratified by quartiles of DGF duration are shown in Figure 4B. 
Discussion 
Recipients of deceased donor kidney transplants who have developed DGF were more likely to 
experience graft loss compared to those who did not develop DGF. More importantly, we have 
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shown a linear association between duration of DGF requiring dialysis and graft loss, such that 
prolonged DGF beyond 7 days posttransplant was associated with a more than 40% greater risk 
of DCGL. We have also found that acute rejection explained less than 10% of the effects 
between DGF duration and allograft outcomes, suggesting other mechanistic pathways, apart 
from acute rejection alone, may have influenced the long-term graft outcomes in deceased donor 
kidney transplant recipients.   
 
The causative pathway resulting in DGF is often multifactorial, including immunological and 
nonimmunological factors that are present during organ procurement and immediately 
posttransplantation 
3,8
. Irrespective of the causative event(s) that result in DGF, the relationship 
between the severity of DGF and allograft outcome remains uncertain. One prior study reported 
that DGF duration exceeding 6 days was associated with adverse long-term allograft survival 
compared to DGF of less than 6 days; whereas patients with DGF duration of less than 6 days 
had similar allograft survivals to those without DGF 
10
. In another study of 1412 kidney 
transplant recipients, duration of DGF (defined as requiring dialysis within the first week 
posttransplant) exceeding 15 days was associated with over 3-fold increased risks of DCGL and 
overall graft loss at 12-months posttransplant compared to recipients without DGF. Recipients 
who had experienced DGF of between 1 to 15 days had similar allograft survival up to 12 
months posttransplant compared to those without DGF 
9
. This study evaluated short-term 
allograft survival and did not establish a linear relationship between duration of DGF and 
adverse allograft survival. Our present study suggested an inverse linear relationship between 
duration of DGF and graft survival, with an apparent DGF threshold effect for DCGL and overall 
graft loss of over 7 days.  
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
14 
 
The ANZDATA registry does not collect data on the number of dialysis sessions required or the 
reasons for initiating dialysis posttransplant, but it is likely that recipients who had received 
dialysis for a short duration posttransplant (ie, 1-4 days) were because of electrolyte (eg, 
hyperkalaemia) and/or water imbalances and therefore may not necessarily represent “true” 
DGF. Nevertheless, differences between studies are likely to reflect the varying definitions of 
DGF and durations of follow-up period. Even though there have been multiple definitions of 
DGF proposed over time, it has been shown in previous studies that no single definition of DGF 
is superior compared to other definitions in predicting the risk of adverse graft outcome after 
kidney transplantation with the use of dialysis within the first week of transplant the most 
preferred and accepted definition 
16,20
. Our study findings also highlight the complexity in 
estimating the clinical significance between DGF and allograft outcome, and that there is a clear 
dose-dependent effect between duration of DGF and allograft loss. 
 
Previous epidemiological studies have shown an independent association between DGF and 
acute rejection, presumably from a reduction in immunosuppression during periods of DGF 
11,13,21,22
. In a cohort study of 645 kidney transplant recipients, the 5-year cumulative 
probabilities of acute rejection in recipients with and without DGF were 23% and 16%, 
respectively
11
. The influence of acute rejection on the effects between DGF on graft outcome 
remains unknown. Several studies have shown the additive adverse effects of DGF and acute 
rejection on graft survival, whereas a small single-center study suggested that the adverse 
association between DGF and graft survival was only evident in those who had developed acute 
rejection 
13,23
. In this study, the effects of DGF on allograft loss were not totally mediated by 
acute rejection, suggesting the observed effects between DGF and allograft loss may result from 
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other unfavorable effects of ischaemic-reperfusion injury rather than a sole intervening 
pathological factor, such as acute rejection that occurs after transplantation. The ANZDATA 
registry does not collect details of the change in immunosuppression following DGF and 
therefore we were unable to explore in detail those recipients who subsequently developed 
rejection-related graft loss or whether a reduction in the intensity of overall immunosuppression 
as a result of DGF was directly responsible for the development of acute rejection and 
subsequent graft loss. Nevertheless, the small number of recipients who had experienced acute 
rejection may have led to erroneous inference and therefore we were unable to generate reliable 
estimates with certainty. 
 
Our study has several strengths and limitations. The prospective nature and the completeness of 
the dataset would suggest that selection and ascertainment biases of the exposure and study 
factors were minimized. Nevertheless, selection bias remained possible because there were likely 
to be systematic differences in the management of kidney transplant recipients with varying DGF 
durations between transplanting centers. Even though we had adjusted for multiple confounding 
factors that were collected and recorded in the registry dataset, there were other unmeasured 
residual confounders, such as changes in the dose, intensity and types of immunosuppressive 
agents, haemodynamic instability, changes to the dose/types of immunosuppressive regimens 
during periods of DGF and use of nephrotoxins or exposure to contrast, which were not collected 
by the ANZDATA registry but may have potentially modified the association between the 
exposure factor and outcomes. It must be acknowledged that ANZDATA registry do not verify 
the accuracy of the data regarding the reporting or nonreporting of acute rejection to the registry, 
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nor does it verify the accuracy of the reporting of allograft loss or DGF. However, the dates of all 
acute rejection episodes and allograft loss were reported to the registry. 
 
Conclusion 
There was a direct dose-dependent effect between the duration of DGF and allograft loss, such 
that DGF duration of at least 14 days was consistently associated with DCGL and overall graft 
loss. Acute rejection accounts for approximately 10% of the effects between DGF and graft loss.  
Future research focussing to identify other potential modifiable mediators that lie in the causal 
pathway between duration of DGF and allograft outcome is critical. Nevertheless, clinical 
interventions that aim to prevent or reduce the duration of DGF per se may potentially improve 
allograft outcomes in susceptible kidney transplant recipients at risk of developing DGF 
posttransplantation.  
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Figure legends 
Figure 1. Unadjusted Kaplan Meier failure curves for death censored graft loss (1A) and overall 
graft loss (1B), stratified by delayed graft function (DGF) status. Log-rank p values for both 
<0.001.  
Figure 2. Proportion of cause-specific death censored graft loss in kidney transplant recipients 
who had experienced delayed graft function (DGF), stratified into quartiles. Causes of death 
censored graft loss included chronic allograft nephropathy (CAN), acute rejection, recurrent or 
de novo glomerulonephritis (GN), vascular complications, BK viral allograft nephropathy 
(BKVAN), nonadherence and other causes.  
Figure 3. Forest plots showing the adjusted hazard ratios (HR) with 95% confidence intervals 
(95%CI) of the association between quartiles of delayed graft function (DGF) duration of 1-4 
days, 5-7 days, 8-13 days and ≥14 days, overall graft loss and death censored graft loss.   
Figure 4. Unadjusted Kaplan Meier failure curves for death censored graft loss stratified by 
quartiles of delayed graft function (DGF) duration of 1-4 days, 5-7 days, 8-13 days and ≥14 
days. Figure 4A shows the curves for the entire cohort (log-rank p value = 0.023) and figure 4B 
shows the curves for the cohort after excluding failed allografts within 1 month post-transplant 
(log-rank p value = 0.012).  
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Table 1. Baseline characteristic of deceased donor kidney transplant recipients with delayed graft function 
stratified by duration of posttransplant dialysis between 1997-2014 (n = 1497).  
 DGF1-4 days  
(n=443) 
DGF 5-7 days 
(n=323) 
DGF 8-13 days 
(n=383) 
DGF ≥14 days 
(n=348) 
p value 
Demographics      
 Age (years, mean [SD])  51.3 (12.5) 49.5 (13.3) 48.6 (13.5) 48.5 (14.4) 0.007 
 Male (n, %)  282 (63.7) 217 (67.2) 255 (66.6) 242 (69.5) 0.373 
 Race (n, %) 
     Caucasian 
     Indigenous 
     Others 
 
334 (75.4) 
40 (9.0) 
69 (15.6) 
 
241 (74.6) 
30 (9.3) 
52 (16.1) 
 
292 (76.2) 
36 (9.4) 
55 (14.4) 
 
259 (74.4) 
33 (9.5) 
56 (16.1) 
0.996 
 Diabetes pretransplant (n, %) 101 (22.8) 58 (18.0) 80 (20.9) 65 (18.7) 0.327 
 Coronary artery disease (n, %) 99 (22.3) 72 (22.4) 84 (22.0) 75 (21.6) 0.993 
 Peripheral vascular disease (n, %) 52 (11.7) 38 (11.8) 47 (12.3) 43 (12.4) 0.991 
 Body mass index (kg/m2, mean [SD]) 27.0 (5.6) 26.5 (5.3) 27.5 (5.6) 27.0 (5.6) 0.141 
 Waiting time (years, mean [SD]) 4.0 (2.6) 4.0 (2.7) 4.3 (2.7) 4.5 (3.1) 0.025 
 Smoking status (n, %) 
     Nonsmoker 
     Former smoker 
     Current smoker 
 
244 (55.1) 
154 (34.8) 
45 (10.1) 
 
170 (52.8) 
113 (35.1) 
39 (12.1) 
 
201 (53.2) 
120 (31.7) 
57 (15.1) 
 
191 (55.5) 
115 (33.4) 
38 (11.1) 
0.467 
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 Cause of ESKD (n, %) 
     Glomerulonephritis 
     Diabetes 
     Cystic 
     Analgesic nephropathy  
     Vascular 
     Others 
 
187 (42.2) 
75 (16.9) 
75 (16.9) 
5 (1.1) 
25 (5.6) 
76 (17.3) 
 
149 (46.1) 
40 (12.4) 
47 (14.6) 
1 (0.3) 
15 (4.6) 
71 (22.0) 
 
175 (45.7) 
53 (13.8) 
55 (14.4) 
3 (0.8) 
27 (7.0) 
70 (18.3) 
 
171 (49.1) 
41 (11.8) 
40 (11.5) 
2 (0.6) 
14 (4.0) 
80 (23.0) 
0.021 
Donor characteristics       
 Age (years, mean [SD]) 48.1 (16.6) 46.7 (16.5) 47.7 (16.1) 47.7 (16.1) 0.688 
 Male (n, %) 230 (51.9) 186 (57.6) 259 (67.6) 207 (59.5) <0.001 
 DCD status (n, %) 87 (19.6) 74 (22.9) 115 (30.0) 82 (23.6) 0.006 
Immunology/Transplant        
 HLA-ABDR mismatches (mean [SD]) 3.4 (1.6) 3.7 (1.6) 3.7 (1.7) 3.6 (1.6) 0.142 
 Peak PRA >50% (n, %) 43 (9.8) 31 (9.8) 44 (11.6) 44 (12.1) 0.001 
 Ischaemic time (hours, mean [SD]) 13.24.7 14.15.1 14.04.9 15.15.1 <0.001 
 Induction (n, %) 
     IL-2RAb (n, %) 
     T cell depleting antibody (n, %) 
     Rituximab (n, %) 
341 (77.0) 
314 (70.9) 
39 (8.8) 
0 (0.0) 
234 (72.4) 
211 (65.3) 
33 (10.2) 
1 (0.3) 
268 (70.0) 
247 (64.5) 
45 (11.7) 
1 (0.3) 
220 (63.2) 
195 (56.0) 
43 (12.4) 
1 (0.3) 
<0.001 
<0.001 
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 Transplant era (n, %) 
    1997-2002 
    2003-2008 
    2009-2014 
 
76 (17.2) 
125 (28.2) 
242 (54.6) 
 
78 (24.2) 
87 (26.9) 
158 (48.9) 
 
97 (25.3) 
111 (29.0) 
175 (45.7) 
 
112 (32.2) 
115 (33.0) 
121 (34.8) 
<0.001 
 Initial immunosuppression 
     Calcineurin-inhibitor (n, %) 
          None 
          Cyclosporin 
          Tacrolimus 
     Antimetabolite (n, %) 
          None 
          Azathioprine 
          Mycophenolic acid# 
     Prednisolone (n, %) 
 
 
15 (3.4) 
155 (35.0) 
273 (61.6) 
 
13 (2.9) 
17 (3.8) 
413 (93.3) 
433 (97.7) 
 
 
12 (3.7) 
126 (39.0) 
185 (57.3) 
 
15 (4.6) 
13 (4.0) 
295 (91.4) 
315 (97.5) 
 
 
13 (3.4) 
150 (39.2) 
220 (57.4) 
 
14 (3.7) 
19 (5.0) 
350 (91.3) 
378 (98.7) 
 
 
14 (4.0) 
194 (55.7) 
140 (40.3) 
 
15 (4.3) 
26 (7.5) 
307 (88.2) 
326 (93.7) 
 
<0.001 
 
 
 
0.215 
 
 
 
<0.001 
Data expressed as number (proportion) or as mean (SD). Comparison of data across groups was undertaken using chi-square test (for categorical 
data) or 1-way ANOVA (for continuous data expressed as mean). DGF – delayed graft function, d – days, ESKD – end-stage kidney disease, HLA 
– human leukocyte antigen, PRA – panel reactive antibody, DCD – donation after cardiac death, IL-2RAb – interleukin-2-receptor antibody. 
#
includes mycophenolate mofetil or enteric coated mycophenolic acid. 
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Table 2. Associations between duration of delayed graft function, death censored graft loss and overall graft 
loss.  
 Death censored graft loss 
Adjusted HR (95%CI) 
Overall graft loss 
Adjusted HR (95%CI) 
Duration DGF 
     1-4 days 
     5-7 days 
     8-13 days 
     ≥14 days 
 
1.00 
1.10 (0.73, 1.67) 
1.45 (1.00, 2.11) 
1.60 (1.10, 2.31) 
 
1.00 
1.25 (0.95, 1.65) 
1.24 (0.95, 1.62) 
1.44 (1.11, 1.88) 
Recipient age (per year increase) 0.98 (0.97, 0.99) 1.01 (1.00, 1.02) 
Donor age (per year increase) 1.02 (1.01, 1.03) 1.01 (1.01, 1.02) 
Total ischaemic time (per hour increase) 0.98 (0.95, 1.01) 0.99 (0.97, 1.01) 
Race 
     Caucasian 
     Indigenous 
     Others 
 
1.00 
1.99 (1.32, 2.99) 
1.21 (0.83, 1.78) 
 
1.00 
2.07 (1.54, 2.79) 
1.24 (0.94, 1.63) 
HLA-mismatches (increase in 1 mismatch) 1.07 (0.99, 1.16) 1.04 (0.98, 1.11) 
DCD status 0.70 (0.43, 1.14) 0.78 (0.56, 1.08) 
PVD 2.11 (1.40, 3.17) 1.59 (1.20, 2.10) AC
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Transplant era 
     1997-2002 
     2003-2008 
     2009-2014 
 
1.00 
0.86 (0.62, 1.19) 
0.71 (0.44, 1.16) 
 
1.00 
0.79 (0.8=63, 1.00) 
0.74 (0.52, 1.04) 
Data expressed as adjusted hazard ratio (HR) with 95% confidence intervals (95%CI). DGF – delayed graft function, DCGL – death censored graft 
loss, DCD – donation after circulatory death, HLA – human leukocyte antigen, PVD – peripheral vascular disease 
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Table 3. Estimates from the counterfactual framework of causality model of the direct and indirect effects of 
delayed graft function on death censored graft loss and overall graft loss. 
Death censored graft loss Estimates (95% confidence intervals) p value 
Controlled direct effects 
Natural direct effects 
Natural indirect effects 
Total effects 
 
Proportion mediated: 0.084 
1.134 (0.980, 1.312) 
1.134 (0.980, 1.312) 
1.01 (0.996, 1.026) 
1.146 (0.992, 1.324) 
0.092 
0.092 
0.154 
0.065 
Overall graft loss Estimates (95% confidence intervals) p value 
Controlled direct effects 
Natural direct effects 
Natural indirect effects 
Total effects 
 
Proportion mediated: 0.087 
1.248 (1.053, 1.478) 
1.248 (1.053, 1.478) 
1.019 (1.001, 1.037) 
1.271 (1.075, 1.504) 
0.011 
0.011 
0.038 
0.005 
Models adjusted for recipient age, donation after circulatory death status and total ischaemic time. Controlled effects correspond to a scenario 
whereby the relationship between the exposure (duration of delayed graft function) and the mediator (acute rejection) is “fixed” at a hypothetical 
given value or threshold, whereas natural effects correspond to a scenario in which the” natural” relationship between the exposure and the 
mediator is maintained (ie, not fixed). The proportion of total effects between the exposure (duration of delayed graft function) and allograft 
outcomes (death censored graft loss and overall graft loss) that were mediated by direct effects (ie, the part of the relationship between the DGF 
duration and overall and death censored graft loss that was not mediated by acute rejection) and indirect effects (ie, the part of the relationship 
between the DGF duration and overall and death censored graft loss that was mediated by acute rejection) are shown.  AC
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